With its first FDA approval in hand for a complement inhibitor designed to treat paroxysmal nocturnal hemoglobinuria (PNH), Apellis Pharmaceuticals has thrown down the gauntlet this week by launching its commercial challenge to longtime PNH leader Alexion Pharmaceuticals, whose two blockbusters dominate the space . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge